BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 25, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Meridia sibutramine regulatory update

EMEA's CHMP recommended the suspension of marketing for anti-obesity sibutramine from Abbott after a safety review indicated an increased risk of cardiovascular events. CHMP said physicians in Europe should not issue any new prescriptions...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >